论文部分内容阅读
目的:探讨辛伐他汀联合非诺贝特治疗混合性高脂血症的临床效果。方法:选取2012年6月~2013年6月我院内二科收治的混合性高脂血症患者140例,随机分为实验组及对照组,采用贯序治疗,即实验组先应用辛伐他汀治疗4周,然后停用辛伐他汀,应用非诺贝特治疗1周,200mg/d。最后停用非诺贝特,继续辛伐他汀治疗3周,而对照组应用辛伐他汀治疗8周。结果:治疗后实验组显效46例,有效19例,无效5例,总有效率92.8%;对照组组显效32例,有效27例,无效11例,总有效率84.3%。实验组总有效率高于对照组,且差异具有统计学意义(P<0.05)。而且实验组血脂改善情况也显著性优于对照组(P<0.05)。结论:应用辛伐他汀联合非诺贝特贯序治疗混合性高脂血症效果显著,可有效改善患者血脂情况,建议在临床治疗中推广应用。
Objective: To investigate the clinical effect of simvastatin combined with fenofibrate in the treatment of mixed hyperlipidemia. Methods: From June 2012 to June 2013, 140 patients with mixed hyperlipidemia admitted to our hospital from June 2012 to June 2013 were randomly divided into experimental group and control group. Sequential treatment was used. The experimental group received simvastatin After 4 weeks of treatment, simvastatin was discontinued and fenofibrate was administered for 1 week at 200 mg / day. Finally, fenofibrate was discontinued, simvastatin treatment was continued for 3 weeks, and the control group was treated with simvastatin for 8 weeks. Results: In the experimental group, 46 cases were markedly effective, 19 cases were effective, 5 cases were ineffective and the total effective rate was 92.8%. In the control group, 32 cases were markedly effective, 27 cases were effective and 11 cases were ineffective. The total effective rate was 84.3%. The total effective rate in experimental group was higher than that in control group, and the difference was statistically significant (P <0.05). Moreover, the improvement of blood lipids in the experimental group was also significantly better than the control group (P <0.05). Conclusion: The combination of simvastatin and fenofibrate sequential treatment of mixed hyperlipidemia significant effect, which can effectively improve the patient’s blood lipids, it is recommended in the clinical treatment of the promotion and application.